Track topics on Twitter Track topics that are important to you
Ajdovšcina, Slovenia, June 8, 2015 / B3C newswire / -- BIA Separations, the world leading developer and manufacturer of CIM® (Convective Interaction Media) monolithic chromatographic columns and process development services strike partnership with Labena d.o.o., one of the leading providers of solutions for process and laboratory analytics in the area of South Eastern Europe.
»BIA Separations` main focus has always been products for manufacturing of biological drugs, viral vectors, vaccines. The gene therapy market started to grow exponentially within the last year and the demand for our services greatly increased, so we have decided to put all our efforts here«, said Ales Strancar.
»This has driven our decision to enter into a partnership with Labena which will begin to distribute BIA Separations products in the area of South Eastern Europe. In addition, the CRO laboratory, which offers services for pharmaceutical companies providing generic drugs and smaller molecules, will continue its activities within Labena group of companies. This will allow the CRO laboratory to expand its customers portfolio and improve the service and support to their customers«, Strancar added.
»We are very pleased that we have managed to come up with a mutual agreement with BIA Separations about the takeover of the CRO laboratory of BIA Separation which is one of the most recognized and renowned in the region. Adding a CRO Laboratory with GMP certificate and FDA audit report to Labena Group will have many beneficial effects for our business model and the services provided by the CRO Laboratory in the South East Europe. We see this also as opportunity to expand our business outside our region to other countries of EU zone. Our plan is to invest into further development of activities and services of the CRO Laboratory not only in equipment and manpower, but more important in expanding of services to suitability studies and genetic research for pharmaceutical industry« said Borut Ceh CEO of Labena.
Labena Ltd. is a company that was established in 1993 and provides dedicated analytical solutions in process and laboratory analytics in the field of pharmaceutical, food industry, medical, and petrochemical industry as well as in R&D areas of academic institutions. Mission of Labena is to combine its knowledge in technology and support services with end users’ application and wishes to provide them with the best choice solutions that fit their expectations and needs. Labena has 5 regional offices in Slovenia, Croatia, Bosnia and Herzegovina, Serbia and Macedonia.
For more information visit: www.labena.si.
About BIA Separations
BIA Separations is the only worldwide developer and manufacturer of CIM® Convective Interaction Media -- short monolithic chromatographic columns optimized for the separation and purification of large biomolecules and viral particles on the laboratory and industrial scale. In addition to products, BIASeparations offers process development services as well as customized immobilization of antibodies .
For more information visit www.biaseparations.com.
Borut Ceh, CEO
Original Article: BIA Separations and Labena Start Long Term PartnershipNEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...